



# **Annual Report**

## **International Scientific Association for Probiotics and Prebiotics**

January 1 – December 31, 2010

### **Contents**

Introduction  
Message from the President  
2011 Objectives  
Highlights of 2010 ISAPP Activities  
Board of Directors as of October 1, 2010  
2010 Industry Advisory Committee Member Companies  
ISAPP Publications  
Appendix: Summary of 8<sup>th</sup> Meeting of ISAPP

### **Introduction**

ISAPP is an international non-profit collaboration of scientists dedicated to advancing the science of probiotics and prebiotics. The mission statement of ISAPP is: To engender and disseminate information on high quality, multidisciplinary, scientific investigation in the fields of probiotics and prebiotics, and to advance the development of scientifically substantiated, health-promoting probiotic and prebiotic products worldwide. ISAPP is the only scientific organization dedicated specifically to probiotics and prebiotics, bringing together scientists from all pertinent disciplines, including food science, microbiology, immunology, biochemistry, nutrition, molecular biology and medicine. As a scientific society, ISAPP strives to have all activities focused on science, not the promotion of any specific commercial products.

For additional details, see website [www.isapp.net](http://www.isapp.net)

### **Message from the President, Dr. Glenn Gibson**

A huge thanks to all who contributed to another very busy year for ISAPP - the Board of Directors for their time, energy and enthusiasm, IAC for invaluable support and scientific input, SFA for exciting plans and showing us that the future is secure and all attendees at the annual conference. It is unfair to mention specific names in such a collective effort but Mary Ellen has put in the usual stellar effort to keep the rest of us on track, Duanne was a great Industry Advisory Committee representative to the Board of Directors and Artur has stepped into that role with ease, Francisco for organising everything in Barcelona and Delphine for chairing SFA.

It has been a hectic year for probiotics and prebiotics - most importantly the science has progressed. But, the field has never had such high profile given the deliberations over



legislation, claims, new products, endless media references and even a new probiotic DVD featuring several ISAPP loyalists! This has meant that we, as an organisation, have had a lot to deal with and consider responding or adding to. It is hard to keep everyone and every situation happy but I have been very proud indeed of the way ISAPP has conducted itself again and the noticeable increased demands on our time is just one indicator of success. Long may that continue. We are still a young organisation, less than a decade old, yet the infrastructure we have and the team ethos that abounds is excellent.

As with each previous year of our existence, we enjoyed a hugely successful annual event. This time in Castelldefels just outside of Barcelona. The science came first as always - great talks and workshops, but the sun and location were terrific too. This was our largest conference yet and placed many demands on the organisers. At one stage, Francisco was even trying to fix the air conditioning system. Who says that that world leading gastroenterologists cannot multi-task! Of course, it would not be an ISAPP event without the serious business of a competitive social event. Amid much "rehydration" the lot of us descended onto the beach to disturb the locals, invade the calm and partake of sporting events. Teams were allocated and football, volleyball, treasure hunt, relay and other forms of public humiliation endured. The skill level was intense (or should that say 'in tents') and the competitive spirit was inspirational (or should that say 'perspirational'). At one stage, local sporting heroes Rafael Nadal and Lionel Messi were spotted in the vicinity. Both were rumored to have agreed that they had wasted their careers given the superhuman efforts on display at the beach. For the record Team "BlackCats" romped home for a fully deserved win, crushing all the other opposition, despite being the only side who refrained from cheating, bribery and collusion.

In January of 2011, the Board of Directors met over a weekend to plan the 10 year vision for ISAPP and review where we are and where we would like to go. This extremely stimulating meeting has generated some new plans and initiatives that we hope consolidate and expand our success. We aim to be the world leading scientific organisation that sets the agenda in our disciplines: determination + ideas to achieve this are on the way!

Planning is going very well for our 2011 meeting in Berkeley this October. Mary Ellen and Michael have worked hard on the venue and other logistics. The invitations are going out and the subject areas promise to maintain the scientific excellence we pride ourselves on. Next year is a big one - we will be 10 years old and plan something special. Then we become teenagers, which is an acronym for grumpy and expensive. We promise to be neither!

As President of ISAPP, I have the best and easiest job in the world. With everyone else involved, it just "happens."

## **2011 Objectives**



- ISAPP will be celebrating its 10<sup>th</sup> anniversary in 2012. The Board will review ISAPP objectives, activities and priorities for our next 10 years. This discussion will be initiated with a meeting January 15-16, 2011 of the BOD met in Toronto. Included will be an effort to update the ISAPP website, logo and mission statement, to be completed in time for the 2012 meeting in Ireland.
- Create a council composed of scientists with a history with ISAPP, to advise the board and take on special projects.
- Continue to respond in a considered and science-based manner to the challenges of different regulatory frameworks involving health benefit claim substantiation.
- Continue to build on a case-by-case basis working relationships with collaborative organizations, such as AGA, ILSI Europe, ILSI North America, World Gastroenterology Organisation and other potential partner organizations interested in advancing the science and communication for probiotics and prebiotics.
- Continue to work with Food Chemical Codex (part of the United States Pharmacopeia) and a team of specialists in lactic acid bacteria to develop a monograph for live microbial cultures. The hope is that this will be a first step toward establishing standards for the use of live microbes in foods.

### **Highlights of 2010 ISAPP Activities**

- The Board of Directors prepared a letter to the editor of British Journal of Nutrition expressing concerns about the situation with EFSA review of probiotic and prebiotic claims in Europe. This letter will be published in early 2011.
- On behalf of ISAPP, Mary Ellen Sanders attended a meeting of the European Food Safety Authority (EFSA) NDA committee with stakeholders to discuss guidance on the scientific requirements for health claims related to gut and immune function, held in Amsterdam, Dec 2, 2010. A meeting report was filed.
- Probiotics and Prebiotics Webinar Lecture Series. ISAPP partnered with the American Gastroenterological Association and the International Life Sciences Institute-North America to offer four lectures:
  - Human Gut Microbiota and Health - Robert Rastall, Ph.D./Glenn Gibson, PhD.
  - Interventions to Influence Health and Disease with Probiotics - Karen Madsen, PhD.
  - Clinical Endpoints Using Probiotics and Prebiotics for IBD, IBS, and Infectious Diarrhea - Fergus Shanahan, MD.
  - Practical Guidelines on Probiotics and Prebiotics Use - Michael Cabana, MD, MPH.

These lectures are archived and available free of charge at:

<http://www.gastro.org/probiotics-and-prebiotics-webinars>. In addition, a written summary of these presentations is submitted for publication: Wallace TC, Guarner F, Madsen K, Cabana M, Gibson G, Hentges E, Sanders ME. Human Gut Microbiota and Their Relationship to Health and Disease. In Press, Nutrition Reviews.

- Mary Ellen Sanders is on a committee organized by Food Chemical Codex (the food ingredient arm of United States Pharmacopeia) to write a monograph on live microbial

cultures used in foods. This effort is still underway, with the intent of finalizing the monograph early in 2011.

- ISAPP has submitted comments to the FDA regarding their draft guidance document “Investigational New Drug Applications (INDs)—Determining Whether Human Research Studies Can Be Conducted Without an IND.” US regulatory consultant and long time ISAPP associate, James Heimbach, took the lead in preparing a response, which was embellished after circulating among the board and outside US and European legal counsel. ISAPP’s primary concern with the guidance document is that it proposes to address all human research, but the document does not adequately or appropriately address the lawful conduct of human research on foods in the US *without the need for an IND*. If this guidance is issued, it may have a chilling effect on the willingness of institutional review boards in the US to approve conduct human research without an IND out of fear of FDA reprisal. ISAPP’s comments are found at <http://www.regulations.gov/#!documentDetail;D=FDA-2010-D-0503-0009> and the FDA guidance document can be found at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM229175.pdf>.
- ISAPP Board members Mary Ellen Sanders and Gregor Reid are participating in a University of MD NIH-funded project on Federal Regulation of Probiotics <http://www.law.umaryland.edu/programs/health/events/probiotics/>.

### **ISAPP-sponsored meeting: The 7<sup>th</sup> Joint Rowett-INRA Symposium on Gut Microbiology: New Insights into Gut Microbial Ecosystems**

The meeting (held from 23-25 June 2010) in Aberdeen attracted 235 delegates from 31 different countries and was a great success. All comments from delegates attending the meeting praised the organization and content of the meeting. In this meeting, each of the four main sessions started with a plenary talk of 40 minutes given by a renowned invited speaker focusing on the specific topic of that session. These were followed by 4 – 6 offered talks (25 minute duration) chosen from the submitted abstracts following the session theme. In addition we obtained funding from Scotland Food and Drink, to support a themed session focusing on dietary modulation of the gut microbiota. The two talks included in this session were chosen from the offered abstracts. The final presentation in the meeting was given by the world-famous local microbiologist, Professor Hugh Pennington.

Thus the scientific sessions within the meeting were:

- Session I – Gut Microbial Communities – phylogeny, genomics and function
- Session II – Microbes and the Environment
- Session III – Microbial activities in the Gut
- Session IV – Impact of Microbial Colonisation on the Host



Of the short talks (20min talks followed by 5 min questions), 14 (out of 24) were presented by young scientists (under 35 years of age). On two days there were also long poster sessions (1.5 hr) enabling delegates to view the 233 posters and talk with the presenting authors, who were requested to attend their poster for 1 hour on a designated day. Thus the posters attended on Day 1 corresponded to sessions I and II while those on day 2 were on topics related to sessions III and IV. Many of these posters were presented by young scientists.

As has become accepted practice at this conference, a workshop session took place during one afternoon, during which four workshops run in parallel. These included short 'provocative' presentations designed to generate further discussion by all participants on the workshop topics: 'Omics technologies; Bacteria and the mucosal surface; The mechanisms of action of Probiotics and Prebiotics; and Mechanisms for microbial survival in the gut. The short contributions were selected from the offered abstracts for the meeting. The chairman of each workshop then summarized the main conclusions to all conference delegates during the final conference session.

We were fortunate to obtain sponsorship from a number of other sources for this meeting, and each sponsor was acknowledged on a slide displayed between talks and during breaks between the oral sessions, and the logos of each were prominently displayed inside the front cover of the conference abstracts booklet (enclosed). This sponsorship enabled us pay full costs of the invited speakers, and the costs for the speaker from the USA (Les Dethlefsen) were fully supported by ISAPP. The Award of the grant from FEMS enabled us to assist 18 young scientists from diverse countries to attend the conference by paying proportions of their registration and travel costs depending on the distances they were travelling.

There were several social events organized in conjunction with the conference presenting opportunities for delegates to relax and continue net-working, hopefully fostering future collaborations. These events included a Civic Reception hosted by Aberdeen City Council, the conference dinner and a wrap-up Ceilidh, a traditional Scottish dance. This year the Ceilidh was held in a marquee on the lawn at the Rowett Institute, providing delegates with the opportunity to visit the site where the organizing committee perform their scientific research. Since many of the delegates had themselves visited and worked in our institute in the past this evoked fond memories for many of them. The Ceilidh was enjoyed by all and signaled the end of a very successful conference.

### **ISAPP-sponsored meeting: IPC 2010 - International Scientific Conference on Probiotics and Prebiotics**

ISAPP sponsored the IPC 2010 - International Scientific Conference on Probiotics and Prebiotics held in Kosice, Slovakia. ISAPP board member, Prof. Francisco Guarner, was sponsored to deliver a lecture. The Conference was held on June 15 to 17 in the meeting facilities of the Hotel Double Tree, Kosice. Sponsors of the Conference were acknowledged and included Danone Research, Danisco, Pen & Tec Consulting and S&D Pharma. Scientific partnership with



the Human Microbiome Project, ISAPP, ILSI and Japanese Society for Probiotics Science was also acknowledged in all the printed materials (program book, list of participants, conference proceedings).

The organizers reported a total of 350 registered delegates from 86 different countries (North and South America, Europe, Africa and Asian-Pacific countries). Most of the audience was international. Most delegates were basic scientists from areas of microbiology, pharmacology and immunology, and a few clinicians, mostly Eastern Europeans. The scientific program included 22 Keynote Lectures, around 30 oral presentation of submitted abstracts and around 90 poster presentations. There were speakers from US, Canada, Australia, India, Japan, New Zealand, Brazil, and most West and Eastern European countries. Attendance to the sessions was high, with an average numbers of 200 or more delegates in the room.

The program can be downloaded from the web site [www.probiotic-conference.net](http://www.probiotic-conference.net). In summary, the organizers merit credit for the ability to attract a large number of international participants.



## Board of Directors October 1, 2009 – September 30, 2010

### *President*

Glenn Gibson, PhD  
Food Microbial Sciences Unit  
School of Food Biosciences  
The University of Reading  
Whiteknights  
PO Box 226  
Reading  
RG6 6AP UK  
Tel: +44 (0)118 935 7220  
Fax: +44 (0)118 935 7222  
g.r.gibson@reading.ac.uk  
www.fst.rdg.ac.uk/research/fmsu/Index.html

### *Vice President*

Todd Klaenhammer, PhD  
Department of Food Science  
North Carolina State University  
P.O. Box 7624  
Raleigh, NC 27695-7624 USA  
919-515-2972  
919-515-7124 fax  
klaenhammer@ncsu.edu

### *Past President*

Gregor Reid, BS. Hons PhD MBA  
Lawson Health Research Institute  
Room F2-116, 268 Grosvenor Street  
London, Ontario, N6A 4V2, Canada  
Tel: 519-646-6100 x65256; Fax: 519-646-6031.  
Laboratory, Lawson Health Research Institute,  
Room 369  
Tel: 519-646-6100 x65120  
gregor@uwo.ca

### *Secretary*

Michael Cabana, MD MPH  
Associate Professor of Pediatrics  
Director, Division of General Pediatrics  
University of California, San Francisco (UCSF)  
3333 California Street, Suite 245  
San Francisco, CA 94118  
(415) 514-2660  
michael.cabana@ucsf.edu

### *Treasurer*

Karen Scott PhD  
Microbial Ecology  
Gut Health Division  
Rowett Research Institute  
Greenburn Road  
Bucksburn  
Aberdeen  
AB21 9SB  
Tel: 01224 712751 ext 2224  
K.Scott@rri.sari.ac.uk

### *2010 Program Chair*

Francisco Guarner, MD PhD  
Digestive System Research Unit  
University Hospital Vall d'Hebron  
Passeig Vall d'Hebron, 119  
Barcelona 08035, Spain  
Tel: (34) 932746282  
Fax: (34) 934894456  
fguarnera@medynet.com

### *Members at Large*

Nathalie M. Delzenne, PhD  
Université Catholique de Louvain  
Unité PMNT  
Pharmacocinétique, Métabolisme, Nutrition &  
Toxicologie  
Avenue Mounier 73, PMNT 7369  
1200 Brussels  
Belgium  
Phone: 32 2 764 73 67  
Fax: 32 2 764 73 59  
delzenne@pmnt.ucl.ac.be

Colin Hill BSc MSc PhD DSc MRIA  
Professor of Microbial Food Safety  
Microbiology Department  
Alimentary Pharmabiotic Centre  
Food for Health Ireland  
University College Cork, Ireland  
+353-21-4901373  
[c.hill@ucc.ie](mailto:c.hill@ucc.ie)  
(Joined the Board of Directors February 2010)



*Executive Director*  
Mary Ellen Sanders, PhD  
Dairy and Food Culture Technologies  
7119 S. Glencoe Ct.  
Centennial, CO 80122-2526 USA  
303-793-9974 phone  
mes@mesanders.com

*Industry Advisory Committee Senior  
Representative*  
Duane Charbonneau, PhD  
P&G

*Industry Advisory Committee, Junior  
Representative*  
Arthur Ouwehand, PhD  
Danisco



## 2010 Industry Advisory Committee Member Companies

Abbott Nutrition	Institut Rosell
Agropur	Kellogg
Beneo-Orafti	Kraft
Biocodex	Mead Johnson
BioGaia	Merck
Boehringer Ingelheim GmbH	Nestle
Cargill	Pfizer Nutrition/Pfizer Consumer Healthcare
CDRF	Probi
Chr. Hansen	Procter & Gamble
Danisco	Unilever
Danone	Valio
Dow	Winlove
FrieslandCampina Domo	Yakult
General Mills	

**2010 ISAPP publications. This list includes summaries of some group discussions at annual meetings as well as other ISAPP-related activities. (For full list of publications see <http://isapp.net/activities.asp#publications>)**

- Guarner F, Sanders ME, Gibson G, Klaenhammer T, Cabana M, Scott K, Reid G, Delzenne N, Fahey G, Hill C. Probiotic and prebiotic claims in Europe: seeking a clear roadmap. Accepted to Brit J Nutr.
- Wallace TC, Guarner F, Madsen K, Cabana M, Gibson G, Hentges E, Sanders ME. Human Gut Microbiota and Their Relationship to Health and Disease. In Press, Nutrition Reviews.
- Sanders ME, Salminen S, Heimbach JT, Pot B, Tancredi D, Lenoir-Wijnkoop I, Bañares S, Lähteenmäki-Uutela A, Gueimonde M. Health claims substantiation for probiotic and prebiotic products. Submitted Gut Microbes.
- Monachese M, Cunningham-Rundles S, Diaz MA, Ermond E, Guerrant R, Hummelen R, Kemperman R, Kerac M, Kort R, Merenstein D, Panigrahi P, Ramakrishna B, Safdar N, Shane A, Trois L, Reid G. Probiotics and prebiotics to combat enteric diarrheal diseases and HIV in the developing world: a consensus report. Submitted to Gut Microbes.
- Champagne CP, Ross RP, Saarela M, Hansen KF, Charalampopoulos D. Viability assessment of probiotics as concentrated cultures and in food matrices. Submitted to Appl Environ Microbiol.
- O'Flaherty S, Saulnier D, Pot B, Versalovic J. How can probiotics and prebiotics impact mucosal immunity? Gut Microbes 2010; 1(5): 293-300. Open access: <http://www.landesbioscience.com/journals/gutmicrobes/article/OFlahertyGUT1-5.pdf>
- Reid G. 2010. The media and probiotics: provocation or dialogue? International Journal of Probiotics and Prebiotics 5(4):165-168.
- Sanders ME. 2010. International Scientific Association for Probiotics and Prebiotics 2010 Meeting Report. Functional Food Reviews 2:131-140.
- Reid G. 2010. Putting science first – The International Scientific Association for Probiotics and Prebiotics (ISAPP). Functional Food Reviews. 2:124-130.

- Shane AL, Cabana M, Vidry S, Merenstein D, Hummelen R, Ellis CL, Heimbach JT, Hempel S, Lynch S, Sanders ME, Tancredi DJ. 2010. Guide to designing, conducting, publishing, and communicating results of clinical studies involving probiotic applications in human participants. *Gut Microbes* 1:243-253. Open access at <http://www.landesbioscience.com/journals/gutmicrobes/06-ShaneGUT1-4.pdf>.
- Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A, Gareau M, Murphy EF, Saulnier D, Loh G, Macfarlane S, Delzenne N, Ringel Y, Kozianowski G, Dickmann R, Lenoir-Wijnkoop I, Walker C, Buddington R. 2010. Dietary prebiotics: Current status and new definition. *IFIS Functional Foods Bulletin* 7(1):1–19.
- Reid G, Gaudier E, Guarner F, Huffnagle GB, Macklaim J, Munoz AM, Martini M, Ringel-Kulka T, Sartor B, Unal R, Verbeke K, Walter J. 2010. Responders and non-responders to probiotic interventions: how can we improve the odds? *Gut Microbes* 1(3):1-5. Open access at: <http://www.landesbioscience.com/journals/30/article/12013/>
- Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach J, Huys G, Levy D, Mack D, Phothirath P, Constable A, Solano-Aguilar G, Vaughan E. 2010. Assessment of probiotic safety for human use. *Gut Microbes* 1 (3):1-22. Open access at: <http://www.landesbioscience.com/journals/gutmicrobes/article/12127/>

#### **Appendix A. 8th Annual Meeting of ISAPP**

(Note that this meeting report was also published in part as Sanders, ME. International Scientific Association for Probiotics and Prebiotics 2010 Meeting Report. *Functional Food Reviews* 2010; 2(4):131–140.)

The International Scientific Association for Probiotics and Prebiotics (ISAPP) convened its 8th meeting August 28-30, 2010 at the Gran Hotel Don Jaime, Castelldefels, Spain. Hosted by Dr. Francisco Guarner, this by-invitation meeting was attended by 123 participants, including 41 scientists from the ISAPP Industry Advisory Committee and invited delegates, from 23 countries, including Russia, Argentina, Brazil, China, and India, as well as from North America and Europe. This year, ILSI-Europe was invited to be part of the program due to their established Probiotic and Prebiotic Taskforces and the progress they have made in scientific issues related to scientific substantiation of health claims. The program began with a plenary session featuring lectures on the human microbiome projects, the role of indigenous prebiotics and probiotics in human milk, the relationship between gut microbes and metabolic syndrome, pili as a mediator of intimate host-microbe interactions and the role of commensal and pathogenic bacteria on programming of the neonatal immune response. Presentations from ILSI-Europe Taskforce representatives included “Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Results from the ILSI Probiotic Task Force” and “From Prebiotic Concept to Prebiotic Effects: Metabolic and Health Benefits. ILSI Europe Prebiotic Taskforce Report.” In addition, an introduction to a survey that ILSI-Europe conducted on key probiotic questions was presented.

After the plenary lectures, a Late Breaking News session was held. This session is comprised of 5 minute lectures (maximum of 3 slides) which aim to be provocative, and highlight new data, new perspectives or new concerns related to the probiotic and prebiotic industries. The topics included the economic benefits due to public health cost savings from supplementation of infant formula with prebiotics, bovine oligosaccharides, bottlenecks for biomarker validation in clinical studies, a description of the new Probiotics European Scientific Foundation, the Scientific American editorial equating functional

foods with snake oil (Snake oil in the supermarket. September 20, 2010, Scientific American, p. 30. <http://www.scientificamerican.com/article.cfm?id=snake-oil-in-the-supermarket>) and our Past-President's "bucket list" including re-emphasizing adherence of companies to the FAO/WHO definition of what a probiotic is and what the term requires.



**ISAPP board of directors.** Back row, L-R: Karen Scott (Treasurer), George Fahey (Member-at-Large), Arthur Ouwehand (Junior IAC representative), Francisco Guarner (Program Chair), Glenn Gibson (President), Nathalie Delzenne (Member-at-Large), Colin Hill (Member-at-Large), Gregor Reid (Past President). Front row, Duane Charbonneau (Senior IAC Representative), Michael Cabana (Secretary), Mary Ellen Sanders (Executive Director), Delphine Saulnier (SFA President). Missing: Todd Klaenhammer (Vice-President).

### **Discussion Group**

On the second day of the meeting, all meeting participants participated in one of six discussion groups. Discussion group members are listed in Table 1. Key conclusions from these groups follow.

Group 1. Where Pathogenesis and Commensalism Meet. Chair: Todd Klaenhammer, Co-chair: Colin Hill.

Whereas pathogens that cause infectious disease harbor uniquely distinct properties from commensals and probiotics, pathogens and commensals do meet in the gut and face a number of shared environmental challenges. These include survival through gastric juice and bile, competition with the existing microbiota, attachment/retention in the intestinal mucosa, interactions with the immune system, and impacts to health – positively for commensals and negatively for infective pathogens. As a result, the two groups share very similar strategies for survival and competition in this niche, such as pili, fimbriae, bile salt tolerance mechanisms, IgA proteases, IgA binding proteins, and oxidative stress genes. Because many of these factors were first discovered in pathogens, they are often referred to as virulence factors on the basis that inactivation usually impacts the virulence of the pathogen. However, it is not surprising that many innocuous commensal bacteria also share these features. With the application of more genome sequencing and high throughput technologies, it is likely that many genes

encoding structures or strategies previously associated with ‘virulence’ will be identified in commensal bacteria. It is important that a clear distinction is retained between true ‘virulence factors’ (pathogen specific factors such as toxins which damage the host, or internalins which facilitate entry into host cells) and those shared survival and colonization strategies employed by all gut-associated bacteria. This discussion group proposed that a more accurate description of these shared structures or strategies would be “survival, tolerance, or competition” factors.

Group 2. Gut Microbiota and Disease. Chair: Francisco Guarner, Co-chair: James Versalovic.

Presentations and discussion in group 2 aimed at describing characteristics of a “normal” gut microbiota in terms of structure and functions, i.e. microbial composition and activities that are considered to be commonly present in human subjects. A second aim of the group was to review clinical conditions associated with dysbiosis, i.e. associated with abnormal characteristics of the gut microbiota. This double approach was considered as the practical way of gathering the relevant information in order to eventually define a “healthy” gut microbiota. The group included a number of scientists actively involved in projects from the International Human Microbiome Consortium (IHMC, [www.human-microbiome.org](http://www.human-microbiome.org)). These projects are currently going on in the US, Europe and China. The MetaHit study suggests that up to 3-4 million microbial genes and about 20,000 functions encoded by these genes are present in the human gut microbiota (Qin et al. 2010). The NIH Human Microbiome Projects have investigated in depth samples from healthy individuals. These studies have clearly detected age related differences between healthy children and adults. Data from different studies on IBS, IBD, type II diabetes and obesity are providing information about consistent changes in gut microbiota composition. This information can be applied to rational remodeling or "tailoring" of human-associated microbial communities and their associated functions (Preidis and Versalovic. 2009). The group concluded that it is still too early to define the structure of a “healthy” gut microbiota. However, markers associated with disease (microbial signatures) are expected to be available soon. These markers may eventually be useful as diagnostic tools. Prospective studies will be needed to provide information about cause-effect relationships.

- Qin J, Li R, Raes J, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464(7285):59-65.
- Preidis GA, Versalovic J. 2009. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. *Gastroenterology* 136(6):2015-31.

Group 3: Bioactives, the Grand Canyon of our Field. Chairs: Nathalie Delzenne and Glenn Gibson

Each group participant was invited to choose a topic related to bioactivity of probiotics and prebiotics.

*Galactoglucomannan oligosaccharide [GGMO]*. This is an oligosaccharide that has demonstrated functional properties in animal foods. This new candidate prebiotic is isolated from waste materials. The unique galactoglucomannan oligosaccharides may play a role in digestive health and immune function. Animal and in vitro models have been used for testing temulose. The GGMO is a promising prebiotic as based on current evidence. Human trials are to be considered for the future.

*Bacteriocin from Lactobacillus salivarius UCC118*: The bacteriocin-producing probiotic *Lactobacillus salivarius* UCC118 alters the composition of the gut microbiota in diet-induced obese mice. Research has focused on (i) understanding the links between diet, gut health, inflammation and metabolic function and (ii) the identification of food components that impact the development of obesity and associated

metabolic abnormalities and the underlying mechanisms by which these effects occur. UCC118 reduced Actinobacteria but increased Bacteroidetes in a model with diet induced obesity.

*Gnotobiotic mouse models.* This presentation addressed the role of the gut microbiota in host physiology and metabolism using gnotobiotic mouse models. Research is especially focused on the mechanisms by which the gut microbiota contributes to the pathogenesis of obesity, insulin resistance, diabetes and atherosclerosis. Mice kept under germ-free conditions have reduced adiposity compared with colonized mice. Lipidomics demonstrated that the gut microbiota had global effects on the host's lipid metabolism, characterized by increased hepatic and adipose triglyceride levels.

*Butyrate.* Butyrate is an important short chain fatty acid metabolite produced during anaerobic fermentation by gut bacteria, which helps maintain a healthy gut. Butyrate is the preferred energy source for gut epithelial cells, and induces apoptosis of cancer cells. Butyrate production also helps to maintain a slightly acidic colonic pH, thereby assisting in pathogen exclusion. Some of the more abundant gut bacteria produce butyrate, including *Faecalibacterium prausnitzii* and *Roseburia* spp. Other bacteria synthesise butyrate from other bacterial metabolites including lactate. Production of butyrate is substrate-dependent, and growth on starch and fructo-oligosaccharides (prebiotics) results in butyrate production.

*Bile acid signatures.* This research explored the influence of the gut microbiota on the bile acid signatures of host tissue compartments and the potential for the gut microbiota to modulate the signalling capacity of these trans-genomic metabolites. This work utilised a targeted High pressure liquid chromatography-mass spectroscopy approach to characterise the bile acid signatures in the liver, kidney, heart and plasma of conventional, germ-free, and antibiotic-treated rats. In addition, work explored the impact of binge-drinking on cognition in humans. The aim of this study was to screen a wide range of urinary metabolites using a <sup>1</sup>H nuclear magnetic resonance (NMR) spectroscopy-based metabonomic approach to establish the relationship between metabolic effects of alcohol consumption and cognitive impairment. The initial phase of this study has demonstrated an association between urinary markers and specific forms of cognitive impairment (spatial working memory). These markers are also linked to gut microbial metabolism.

*Gut flora and metabolic syndrome.* The field of interest is the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. Research covers the fundamental mechanistic aspects of the host-gut microbes interactions, as well as the impact of nutritional modulation of the gut microbiota by using pre- and probiotics. Special attention is given to the role of the endocannabinoid system and its impact on the control of gut barrier function and adipogenesis. Future strategies on the role of probiotics and prebiotics in metabolic syndrome were discussed.

*Immunomodulation.* The aim is to isolate and identify the effector molecule produced by *L. reuteri* that is capable of inhibiting TNF production from activated human myeloid cells. This has been done using a combination of mass spectroscopy and NMR techniques. The second objective is to understand the mechanism of probiotic-mediated TNF suppression.

*Phenylpropanoid compounds.* Current research focuses on phenylpropanoid-derived compounds in the diet that are released and transformed by the colonic microbiota to form anti-inflammatory

metabolites. Particular compounds of interest are ferulic acid and its derivatives. These compounds undergo de-esterification hydrogenation, demethylation and dehydroxylation by the gut bacteria. Species responsible for these molecular transformations are being described with a view to development as potential probiotics.

*Gut flora and xenobiotics.* Research focuses on the metabolic interactions between the gut microbiota and its host metabolism, with a particular interest on the liver and the brain. The complex relationships between drugs, drug metabolism and the gut flora was described and the effect of dietary modulation. In this context, antibiotics as a means to modulate the host metabolism through alteration of the microflora and xenobiotic metabolism may lead to new research on pro and prebiotics.

*Fatty acids and the gut.* The focus was on the interactions between fatty acids and commensals in the gastrointestinal tract. This interaction between administered microbes and fatty acids could result in a highly effective nutritional approach to the therapy of a variety of inflammatory and neurodegenerative conditions. For the specific case of conjugated linoleic acid, its anti-proliferation effect was described. Species of bifidobacteria may produce conjugated linoleic acid at varying levels.

Immunoglobulins. Urinary metabolic and mucosal immunoglobulin responses of the pig to nutritional intervention around the weaning period indicated that *B. lactis* has a differential effect on both of these parameter sets depending on the initial weaning diet, even after a dietary washout period.

*Antiadhesive activities of prebiotics.* Prebiotics are generally thought of as fermentation substrates, manipulating the microbiota composition and activity. Oligosaccharides can, however, act as antiadhesive agents, preventing pathogens from binding to host cell receptors. These oligosaccharides are being developed as an approach to therapy, typically involving complex multivalent derivatives. There is, however, accumulating evidence that galacto-oligosaccharides also have the ability to prevent pathogens from binding to cells, although the evidence for an effect *in vivo* is currently lacking. This type of activity could, however, be a feature in design of future prebiotic oligosaccharides.

The group concluded with general discussion to ascertain whether bioactives were capable of inducing similar health benefits to probiotics and prebiotics and/or explaining mechanisms of effect. The question was raised as to whether bioactive compounds could be a new market with nutrition/medical applications.

Group 4: Probiotics and Prebiotics in Perinatal Nutrition. Chair: Michael Cabana; Co-chair: David Mills

This group discussed the increasing use of probiotics and prebiotics by infants and young children. One effect of these dietary agents is changes in the infant microbiota. Attempts to define the 'normal' or 'typical' infant microbiota, metagenome and metabolome were discussed. There are many confounding factors to these efforts, such as mode of delivery, antibiotic exposure, breastmilk exposure and gestational age. In addition, there are no accepted standards for stool collection. Stool itself may be an imperfect representation of the microbiota; however, given the limitations of current technology, it would not be ethical to use more invasive methods in well infants. Definition of the infant microbiota may allow us to find correlations with infant disease states, as well as develop biomarkers for clinical trials. Experiences were shared among group participants on attempts to manipulate the gut microbiota by probiotics and prebiotics. In addition, human breast milk as a delivery agent for prebiotics and

microbes was discussed. The potential of adding human milk oligosaccharide mimics to infant formula was also discussed. In addition, the potential long-term impact of infant formula products supplemented by probiotics and prebiotics on long-term infant health was considered.

Group 5. Health Benefit Claims for Probiotic and Prebiotic Products. Chair: Mary Ellen Sanders, Co-Chair: Seppo Salminen.

This group discussion opened with brief descriptions of differences among regulatory frameworks for probiotics in the United States, Canada, Europe, China and India. All these geographical regions had in common the principle of consumer protection, although the means to this end varied. There was agreement that health claims should be substantiated by generally accepted scientific evidence, taking into account the totality of the available scientific data, and weighing this evidence to determine the strength of the support.

Of note, although both the US and Europe allow disease risk reduction claims, in the US foods have not been allowed to be used to reduce the risk of acute diseases, such as colds or flu, but in Europe this is in theory possible, if evidence is provided. India is in the process of developing specific probiotic guidelines and it is still possible to provide scientific input into this process.

Discussion about the wording of health claims emphasized that this is a very difficult endeavor. It often entails translating complicated scientific findings into claims that can be understood accurately by average consumers. Companies must first define what the most important message is, and then use wording that is simple, not vague, confusing or misleading and that accurately reflects the strength of the scientific evidence.

Another issue that was of concern regarding developing substantiation for claims is this issue of biomarkers. In Europe, this has a special importance, as the regulation specifically indicates that a change in a risk factor must be established in addition to convincing evidence directly on the endpoint, if needed. However, in the field of probiotics and prebiotics, few valid biomarkers are available for the types of endpoints these substances target. Furthermore, considering that regulators are focused on the role of foods in health, there is a great need for valid approaches for evaluating health instead of disease. Biomarkers would also be very useful for identifying subpopulations of responders and non-responders, to increase the focus of human studies.

Important themes that emerged during this discussion:

- Regarding the difficulty in measuring health, the focus of studies could be in measurement of homeostasis. From a statistical point of view, if a study were able to minimize the variation around the mean for a specific measure (even in the absence of changing the mean), it could be a reflection of improved health, assuming a biological rationale exists that tighter control of the parameter is physiologically advantageous. In other words, lessening the fluctuation around an individual's biomarker could be interpreted as contributing to improving health. This novel idea emphasizes the importance of homeostasis as a focus of studies on health, and provides a rationale based in solid statistical theory as a way to measure this.
- Another issue that emerged was the frustration about regulatory "boxes." Although scientists would agree that there is a continuum between health and disease, in regulatory terms these are distinct states. Likewise, there are numerous examples of foods having pharma-like properties, such

as reducing the risk of acute infections. However, some regulatory authorities see such actions as only valid for “drugs.” The consequences of such constraints can be significant for scientists and the studies they design, for consumers and how they might benefit from certain products.

Group 6. Probiotics and Prebiotics to Combat Enteric Diarrheal Diseases and HIV in the Developing World. Chair: Gregor Reid, Co-Chair: Dan Merenstein.

This discussion group comprised experts from the developing world, others who had worked on projects there, and participants committed to helping with this major morbidity and mortality problem. All were positive about the evidence to date and potential for probiotics and prebiotics to help lower the burden of disease and suffering in a cost effective manner that could engage and empower local people in developing countries such as Tanzania, Kenya, Rwanda, South Africa, Ghana, India, Bangladesh, Pakistan, China, Brazil and Peru. This group aimed to build upon ISAPP’s commitment to consider issues in developing countries and attempt to bring probiotic and prebiotic concepts and products to these regions. Furthermore, the group was interested in a follow-on discussion from the Gates Foundation meeting in London, UK (January 2010), which concluded that no funding was yet warranted for use of probiotics for diarrhea in developing countries.

The group addressed the following issues:

1. Determine the scientific rationale for using probiotics and/or prebiotics to combat diarrheal diseases and/or HIV/AIDS in the developing world.
2. Write practical recommendations for prebiotics and probiotics on issues such as choice of: probiotic strains, prebiotic, dosages, appropriate target diseases, test populations. Other issues to address include how to deliver the products in challenging settings, how to offset the cost of the treatment and use of unique, effective models.

With an eye to the issues stated above, there were three objectives for the session:

1. Try to set up collaborations leading to projects in the developing world.
2. Write a roadmap for how to bring probiotics to a developing country, even if only for research and not for profit.
3. Create project ideas that can identify plausible mechanisms whereby “biotics” combat diarrheal diseases and HIV.

Studies were proposed that would address the impact of pro/prebiotics on HIV/AIDS or on diarrheal diseases. Specific issues of best measurement endpoints, study population, confounders and other issues were considered.

Recommendations were made on how to facilitate progress in this area.

1. Products calling themselves ‘probiotic’ are slowly becoming available in developing countries, but the majority have never been clinically tested and shown to confer a health benefit. This is a major failing of companies and government agencies. Either products should be appropriately tested or the word ‘probiotic’ removed from the labels.
2. The group discussed studies showing that probiotics and prebiotics could provide viable tools for management of diarrheal diseases and HIV/AIDS.



3. Funding for research and young scientists is a major problem in the developing world. The suggestion was made that ISAPP could solicit funds from its Industry Advisory Committee members to set up a program to provide funding (~\$40,000-50,000) for:

- (i) Two studies per annum for developing world scientists, possibly in collaboration with ISAPP-selected scientists from developed countries, targeting this research area.
- (ii) Fund an African junior faculty member, to enable him/her to spend 1 year working in an established program to learn methodologies, grant writing, collaboration skills, and how to conduct independent research. This person would be selected by his/her department, with the stipulation that the department would provide ongoing research support.



**Participants in discussion group 6: Probiotics and Prebiotics to Combat Enteric Diarrheal Diseases and HIV in the Developing World (see Table 1).**

### **Student and Fellow Association**

The newly formed Student and Fellow Association convened two programs: a poster session and “Opportunities Everywhere” informal session.

#### *Poster session Student and Fellow Association (SFA)*

Eight young researchers who were awarded travel grants to attend the meeting presented their research as posters. Subjects ranged from mucosal immunity and Crohn’s disease to HIV and the developing world.

- Annett Klinder, University of Reading, United Kingdom “Higher fruit and vegetable consumption increased butyrate producing bacteria in *Faecalibacterium prauznitzii* in human volunteers.”
- Ruben Hummelen, Lawson Health Research Institute, Canada “Deep sequencing of the vaginal microbiome among women with HIV.”
- Claire Merrifield, Imperial College, United Kingdom, “Weaning Diet Initiates a Sustainable Metabolic Reprogramming Event in the Pig that Impacts the Action of *Bifidobacterium lactis*”

- Alicia Murcia, Hospital Vall d'Hebron, Spain "The mature dendritic cell subpopulation is augmented in the intestinal lamina propria of Crohn's disease patients"
- Carissa Thomas, Baylor College of Medicine, United States "Probiotic *Lactobacillus reuteri* suppresses TNF through inhibition of TAB1 and downstream MAPK pathways"
- Maria Alejandra Diaz, Baylor College of Medicine, United States: "Characterization of *Lactobacillus* spp. Isolated from *Tursiops truncatus* for use as Dolphin Probiotics"
- Marc Monachese, Lawson Health Research Institute, Canada "Potential new applications for probiotics in the developing world"

The following promising young researchers were selected to receive the travel grant but were unfortunately not able to attend:

- Alireza Shenavar Masouleh, University of Tehran, Iran, "Molecular Identification of *Leuconostoc mesenteroides* and *Enterococcus faecium* in Persian Sturgeon."
- Valentina Tremaroli, Sahlgrenska University Hospital, Sweden, "Linking immunity and metabolism: microbial signalling through GPR43 and expression of iNOS in the mouse intestine"

#### "Opportunities Everywhere" session

With an astonishing picture of Barcelona in the background, and the glorious (and blocking) view of chair Ruben Hummelen on the fore ground, the SFA held its first seminar targeted specifically for students. Five scientists, who survived all the mistakes that we (students and fellows) are still about to make, contributed to the seminar by sharing their "life-lessons" and experiences. The first speaker, Gregor Reid, emphasized the value of having an external advisor, separate from your supervisor, who may be out of your own field of research, to provide advice and feedback with important decisions.

Michael Cabana gave great examples how in larger multidisciplinary projects the assembly of a team of people who are top notch in their own specific field may be the most important part of a project. The advice of Fredrik Bäckhed on how to survive in increasingly multidisciplinary teams was illuminating: learn different (scientific) languages but stick to what you are best at. Also, we were alerted to the importance of developing our own independent scientific profile, distinct from your former boss. The challenge is taking something with you from your postdoctoral experience that you can independently develop into your own area of expertise. In that way, a fruitful collaboration with your supervisor is still possible and you have the chance to develop an independent profile.

John McCormick challenged us with the question of whether any of us have followed through with an idea that we thought was great, but which our supervisor disagreed with. Two people lit up the session explaining that they have been Bohemians, which meant that they were ready as independent scientists. Also, John advised to only dare to dream about your own lab if you absolutely love your work.

Remco Kort inspired us not to feel limited by doing only what is possible within your group or company as there are many possibilities to blaze your own path by starting your own company or organization. Remco explained that there are many advantages in industry, such as the quick turn over of interesting

ideas and projects. However, because of the customer- or market-driven nature of industry, it makes it difficult to develop and maintain your own unique area of expertise.



**Students meet with professional ISAPP members during the “*Opportunities Everywhere*” session**

### **Extra-Curricular Activities**

The participants of ISAPP 2010 did not miss the opportunity to experience the Mediterranean Sea. After the discussion groups adjourned, all participants hopped on busses for the short 1 mile trip to the sandy beach and blue water. Team activities including Pictionary drawn in the sand, volleyball, soccer, brain teasers, relay races and a treasure hunt were organized. Prizes were awarded at the evening dinner. The following were haikus written under time constraints from the competing teams:

Ten surfers floating boards  
Surrounded by lots of ISAPP researchers playing  
Football, volleyball, treasure hunt, swimming

Nude sunbathing  
Clothes in potato chip bag  
Lying on rocks

The beach was so exotic  
But my gut was way too chaotic  
So I took my probiotic

Volleyball players  
Hitting the ball like crazy  
Impressing the chicks

We saw some winners  
Ruling the whole freakin' beach  
Despite being Dutch

She wears a large hat  
Blowing her whistle loudly  
Focused on the day

Mad Spanish lady  
Blows her top at ISAPP champs  
Running relay races

**ISAPP meeting participants enjoy activities on the beach**



**Sand Pictionary**



**Soccer**



**Relay races**



**Team Orange displays team spirit!**

**Table 1. Discussion group members.**

Last Name	First Name	Affiliation	Country
Discussion group 1. Where pathogenesis and commensalism meet			
Antonsson	Martin	Probi AB	Sweden
Charbonneau	Duane	Procter & Gamble	USA
Christensen	Jeffrey	Chr. Hansen	Denmark
Daly	Charlie	University College Cork	Ireland
Hill	Colin	University College Cork	Ireland
Hutkins	Bob	University of Nebraska	USA
Klaenhammer	Todd	North Carolina State University	USA
Lahtinen	Sampo	Danisco Health & Nutrition	Finland
Lamoureux	Maryse	Agropur	Canada
McCormick	John	University of Western Ontario	Canada
Nes	Ingolf F.	Norwegian University of Life Sciences	Norway
Perdigon	Gabriela	CERELA	Argentina
Peterson	Daniel	University of Nebraska-Lincoln	USA
Pridmore	David	Nestlé	Switzerland
Sako	Tomoyuki	Yakult Europe	the Netherlands
Satokari	Reetta	University of Turku, Finland	Finland
Sleator	Roy	Cork Institute of Technology	Ireland
Discussion group 2. Gut microbiota and disease			
Bienenstock	John	McMaster Brain-Body Institute	Canada
Ehrlich	S. Dusko	INRA	France
Eiberger	Inna	Merck Selbstmedikation GmbH	Germany
Guarner	Francisco	University Hospital Vall d'Hebron	Spain
Haimet	Florence	INRA	France
Hunter	Kirsty	Nottingham Trent University	England
Klinder	Annett	University of Reading	England
Madduri	Krishna	The Dow Chemical Company	USA
Manichanh	Chaysavanh	University Hospital Vall d'Hebron	Spain
Martini	Peggy	Kraft Foods	USA
Menon	Ravi	General Mills Inc	USA
Murcia Muñoz	Alicia	Institut de Recerca, Hospital Vall d'Hebron	Spain
Ouwehand	Arthur	Danisco	Finland
Qin	Junjie	Beijing Genomics Institute	China
Ringel	Yehuda	University of North Carolina at Chapel Hill	USA
Rowland	Ian	University of Reading	England
van Hemert	Saskia	Winclove	the Netherlands
van Hylckama Vlieg	Johan	Danone Research	France
Versalovic	James	Texas Children's Hospital	USA
Discussion group 3. Bioactives, the Grand Canyon of our field			
Bäckhed	Fredrik	University of Gothenburg	Sweden

Bosscher	Douwina	Cargill R&D	Belgium
Cani	Patrice D.	Université Catholique de Louvain	Belgium
Chow	JoMay	Abbott Nutrition	USA
Claus	Sandrine	Imperial College	England
Delzenne	Nathalie	Université Catholique de Louvain	Belgium
Fahey	George	University of Illinois	USA
Gibson	Glenn	University of Reading	England
Lathrop Stern	Lori	Pfizer Consumer Healthcare	USA
Lichtenwald	Kathy	The Dow Chemical Company	USA
Meeuws	Sarah	Winclove	the Netherlands
Meheust	Agnes	ILSI Europe	Belgium
Merrifield	Claire	Imperial College	England
Miller	Barbara	Procter & Gamble	USA
Möllstam	Bo	BioGaia AB	Sweden
Murphy	Maeve	General Mills Inc	USA
Murphy	Eileen	University College Cork	Ireland
Rastall	Robert	The University of Reading	England
Russell	Wendy	Rowett Institute of Nutrition and Health	Scotland
Russell	Mike	Mead Johnson Nutrition	USA
Saulnier	Delphine	ISAPP Student and Fellow Association	USA
Scott	Karen	Rowett Institute of Nutrition and Health	Scotland
Swann	Jonathan	Imperial College London	England
Thomas	Carissa	Baylor College of Medicine/Texas Children's Hospital	USA
Tremaroli	Valentina	Wallenberg Laboratory at Sahlgrenska	Sweden
Discussion group 4. Probiotics and Prebiotics in Perinatal Nutrition			
Cabana	Michael	UCSF	USA
Connolly	Eamonn	BioGaia AB	Sweden
Davis	Steven	Abbott Nutrition	USA
Donovan	Sharon	University of Illinois	USA
Mills	David	University of California	USA
Ringel-Kulka	Tamar	University of North Carolina at Chapel Hill	USA
Ross	Paul	Teagasc Food Research Centre	Ireland
Stahl	Bernd	Danone Centre for Specialised Nutrition	Germany
Szajewska	Hania	The Medical University of Warsaw	Poland
Veereman	Genevieve	Free University Brussels	Belgium
Discussion group 5. Health benefit claims for probiotic and prebiotic products			
Ambrosetti	Lara	Ginsana SA	Switzerland
Bañares	Silvia	University Abat Oliva	Spain
Duffy	Linda	National Institutes of Health	USA
Durmont	Frederic	Lallamand SAS	Switzerland
Fletcher	Reg	Kellogg Europe Trading Ltd	Ireland
Gueimonde	Miguel	Asturian Dairy Products Institute	Spain



Gupta	Rajesh	Biocodex USA	USA
Heimbach	Jim	JHeimbach LLC	USA
Hinkel	Ulrika	Boehringer Ingelheim GmbH	Germany
Jankovic	Ivana	Nestlé	Switzerland
Kozianowski	Gunhild	Beneo Institute	Germany
Kumar	Ashok	Manager - LifeScience Advisory Group	India
Lähteenmäki-Uutela	Anu	University of Turku	Finland
Larsson	Niklas	Probi AB	Sweden
Lenoir-Wijnkoop	Irene	Danone Research	France
Leyer	Gregory	Danisco USA	USA
Macfarlane	Sandra	University of Dundee	Scotland
Mackle	Tami	Pfizer Consumer Healthcare	USA
Morelli	Lorenzo	Institute of Microbiology UCSC	Italy
O' Rourke	Raymond	Food Lawyer	Ireland
Palou	Andreu	University of Balearic Islands	Spain
Polzin	Kayla	Cargill, Inc.	USA
Pot	Bruno	Institut Pasteur Lille	France
Rijkers	Ger	UMC Utrecht and St. Antonius Hospital	the Netherlands
Salminen	Seppo	Functional Foods Forum	Finland
Sanders	Mary Ellen	Dairy & Food Culture Technologies	USA
Sanz	Yolanda	Spanish National Research Council (CSIC)	Spain
Schoterman	Margriet	FrieslandCampina Domo	the Netherlands
Tancredi	Daniel	UC Davis	USA
van Loveren	Henk	National Institute of Public health and the Environment	the Netherlands
Walker	Donald Carey	Mead Johnson Nutrition	USA
Welch	Rob	University of Ulster	Northern Ireland
Zhao	Jia	Yakult Europe	the Netherlands
Discussion group 6. Probiotics and prebiotics to combat enteric diarrheal diseases and HIV in the developing world.			
Cunningham-Rundles	Susanna	Weill Medical College of Cornell University	USA
Diaz	Maria Alejandra	Baylor College of Medicine	USA
Ermond	Eric	Nestec SA	Switzerland
Guerrant	Richard	University of Virginia School of Medicine	USA
Hummelen	Ruben	Erasmus University Medical Center	the Netherlands
Kemperman	Robèr	Unilever R&D	the Netherlands
Kerac	Marko	UCL Centre for International Health & Development / Valid International	England
Kort	Remco	TNO Quality of Life	the Netherlands
Merenstein	Dan	Georgetown University	USA
Monachese	Marc	Lawson Health Research Institute	Canada
Panigrahi	Pinaki	University of Nebraska Medical Center	USA
Ramakrishna	Balakrishnan	Christian Medical College Vellore	India



Reid	Gregor	Lawson Health Research Institute	Canada
Safdar	Nasia	University of Wisconsin-Madison	USA
Shane	Andi	Emory University School of Medicine	USA
Sheveleva	Svetlana	Institute of Nutrition Moscow	Russia
Trois	Livia	Grupo de Apoio a AIDS Pediatric, Children's Hospital Conceicao	Brazil



**8<sup>th</sup> Meeting of the  
International Scientific Association for Probiotics and Prebiotics  
August 28-30, 2010  
Gran Hotel Rey Don Jaime, Castelldefels, Spain**

**PROGRAM**

<b>Friday, August 27</b>
20.00. IAC/BOD garden dinner
<b>Saturday, August 28</b>
8-9:30. Board of Directors meeting (BOD only)
9:30 – noon. Student and Fellow Association “Opportunities Everywhere” session (SFA members and other interested attendees)
10:30. Coffee break
9:30-10:30. IAC-only meeting (IAC-only)
10:30-noon. IAC+BOD meeting (Only ISAPP Board + IAC members)
Noon – 13:30. Lunch (All)
13:30 – 17:00. Plenary session (All) (Abstracts available at <a href="http://isapp.net/meeting_page.asp">http://isapp.net/meeting_page.asp</a> )
13:30 – 14:00. Update on the Human Microbiome Projects. Dusko Ehrlich, Current Chair of Steering Committee of International Human Microbiome Consortium (Francisco Guarner, host)
14:00 – 14:30. Human Milk: Role of indigenous prebiotics and probiotics. Sharon Donovan, University of Illinois, USA (George Fahey, host)
14:30-15:00. Relationship between gut microbes and metabolic syndrome. Fredrik Backhed, Wallenberg Laboratory, Sahlgrenska University Hospital, Göteborg, Sweden (Nathalie Delzenne, host)
15:00-15 :30. Break
15:30-16:00. Pili as a mediator of intimate host-microbe interactions – comparisons among pathogens, commensals and probiotics. Reetta Satokari, University of Turku, Finland (Todd Klaenhammer, host)
16:00-16:30. Effect of Commensal and Pathogenic Bacteria on Programming of Neonatal Immune Response. Susanna Cunningham-Rundles, Weill Cornell Medical College, New York (Gregor Reid, host)
16 :30-16:50. Guidance for substantiating the evidence for beneficial effects of probiotics: Results from the ILSI probiotic task force. Arthur Ouwehand, Danisco
16:50-17:10. From Prebiotic Concept to Prebiotic Effects: Metabolic and Health Benefits. ILSI Europe



Prebiotic Taskforce Report. Bernd Stahl, Danone
17:15 - 18:00. SFA Poster Session, with authors.
18:00 – 19:30. Late breaking news/rapid fire session (Gregor Reid, chair)
19.30 – 19.45. Introduction to “Probiotic Q&A” (Agnes Meheust, ILSI Europe)
20:00. Dinner - Buffet dinner (All)
<b>Sunday, August 29</b>
9:00 – 16:00. 6 discussion/breakout groups (all participants divided among these 6 groups)
1. <b>Where pathogenesis and commensalism meet.</b> Chair: Todd Klaenhammer, Co-chair: Colin Hill.
2. <b>Gut microbiota and disease.</b> Chair: Francisco Guarner, Co-chair: James Versalovic.
3. <b>Bioactive compounds - the Grand Canyon of our field.</b> Chair: Nathalie Delzenne; Co-Chair: Glenn Gibson.
4. <b>Prebiotics and probiotics in perinatal nutrition.</b> Chair: Michael Cabana, Co-Chair: David Mills.
5. <b>Health benefit claims for probiotic and prebiotic products.</b> Chair: Mary Ellen Sanders, Co-Chair: Seppo Salminen.
6. <b>Probiotics and prebiotics to combat enteric diarrheal diseases and HIV in the developing world.</b> Chair: Gregor Reid, Co-Chair: Dan Merenstein.
16.00-20.00. Group activity (All)
20:00. Dinner (All)
<b>Monday, August 30</b>
8:30 AM – noon. Wrap up session – reports from all 6 discussion groups (All) – adjourn meeting
Noon – 13:30. Lunch (All)
13:30 – 15:30. Special IAC/BOD meeting on claims substantiation (IAC, BOD and special invitees only)
14.00 – 17.00. SFA visit to Lab of Dr. Francisco Guarner. Students/fellows only.
15:30 – 16:30. Board of Directors meeting (BOD only)
20.00. Dinner. Transportation will be arranged (IAC + BOD; ILSI – RSVP required)